<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Urology</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Boston Sci’s Rezūm therapy superior to drugs in treating BPH</title>
      <description>
        <![CDATA[Boston Scientific Corp.’s Rezūm Water Vapor Therapy is superior at providing symptom relief for men with benign prostatic hyperplasia (BPH) than combination drug therapy, according to 12-month data from the Vapeur clinical trial. Patients treated with Rezūm, a minimally invasive therapy, also saw a better preservation of their sexual function.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729530</guid>
      <pubDate>Mon, 16 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729530-boston-scis-rezm-therapy-superior-to-drugs-in-treating-bph</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Boston-Scientific-Rezum-Water-Vapor-Therapy-3-16.webp?t=1773694611" type="image/jpeg" medium="image" fileSize="157338">
        <media:title type="plain">Boston Scientific’s Rezūm Water Vapor Therapy</media:title>
        <media:description type="plain">Rezūm Water Vapor Therapy system. Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Sci’s Valencia buy adds ITNS to urology</title>
      <description>
        <![CDATA[Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial nerve stimulator (ITNS) designed to treat urge urinary incontinence (UUI). The companies did not disclose terms of the deal, which is not expected to have a material impact on 2026 earnings per share. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/727811</guid>
      <pubDate>Tue, 13 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727811-boston-scis-valencia-buy-adds-itns-to-urology</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-28-Boston-Science_Global-Headquarters_Marlborough-Mass.webp?t=1603916123" type="image/png" medium="image" fileSize="1708122">
        <media:title type="plain">10-28-Boston-Science_Global-Headquarters_Marlborough,-Mass</media:title>
        <media:description type="plain">Boston Scientific Corp.'s global headquarters in Marlborough, Mass.</media:description>
      </media:content>
    </item>
    <item>
      <title>Surgical robotic maker Shenzhen Edge announces $154M HKEX IPO</title>
      <description>
        <![CDATA[Surgical robotics maker Shenzhen Edge Medical Co. Ltd. reported its initial public offering on the Hong Kong Stock Exchange to raise HKD$1.19 billion (US$154 million) to advance its pipeline of surgical robotic systems and expand its geographic footprint to markets outside China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727307</guid>
      <pubDate>Wed, 31 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727307-surgical-robotic-maker-shenzhen-edge-announces-154m-hkex-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Shenzhen-Edge-Medical-Co.-Ltd.-Multi-Port-Endoscopic-Surgical-Robot-12-31.webp?t=1767210534" type="image/jpeg" medium="image" fileSize="208812">
        <media:title type="plain">Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot</media:title>
        <media:description type="plain">Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot</media:description>
      </media:content>
    </item>
    <item>
      <title>Siemens, Alzpath sign deal on Alzheimer's diagnostic blood test</title>
      <description>
        <![CDATA[Siemens Healthineers AG became the latest company to sign a licensing agreement with Alzpath Inc. to use its pTau217 antibody in the development of a blood-based diagnostic assay for Alzheimer's disease. Alzpath previously signed deals with the likes of Roche AG and Beckman Coulter Diagnostics Inc. to use its pTau217 antibody to create diagnostic tests based for early detection and monitoring of Alzheimer's.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727082</guid>
      <pubDate>Wed, 17 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727082-siemens-alzpath-sign-deal-on-alzheimers-diagnostic-blood-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/research-collaboration-deal-handshake-gloves.webp?t=1765812758" type="image/jpeg" medium="image" fileSize="419449">
        <media:title type="plain">Photo of researchers shaking hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Nephrodite's Holly renal replacement named breakthrough device</title>
      <description>
        <![CDATA[Nephrodite Inc.'s Holly, an implantable, continuous renal replacement system, received U.S. FDA breakthrough device designation as a novel and potentially life-changing treatment for end-stage kidney disease. The system is designed to enable continuous blood filtration and allow patients freedom to go about their days without frequent, hours-long visits to a dialysis clinic or being hooked up to a filtration system at home.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727065</guid>
      <pubDate>Mon, 15 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727065-nephrodites-holly-renal-replacement-named-breakthrough-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Nephrodite-15dec25.webp?t=1765834885" type="image/jpeg" medium="image" fileSize="172150">
        <media:title type="plain">Nephrodite Holly</media:title>
        <media:description type="plain">Nephrodite Inc.’s Holly renal replacement system Credit: Nephrodite Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Proverum, Zenflow secure FDA nod for systems to treat BPH</title>
      <description>
        <![CDATA[The U.S. FDA recently cleared two new medical devices to treat benign prostatic hyperplasia, offering men with enlarged prostates additional treatment options which are minimally invasive. The approvals include Proverum Medical Ltd.’s Provee System and Zenflow Inc.’s Zenflow Spring Implant and Delivery System, both are first-line interventional therapeutic options which offer relief to the millions of men living with the condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727064</guid>
      <pubDate>Mon, 15 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727064-proverum-zenflow-secure-fda-nod-for-systems-to-treat-bph</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Benign-prostatic-hyperplasia-BPH-prostate.webp?t=1745267344" type="image/jpeg" medium="image" fileSize="464489">
        <media:title type="plain">Illustration of human anatomy, enlarged prostate</media:title>
      </media:content>
    </item>
    <item>
      <title>Teleflex selling 3 business units for $2.03B</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Teleflex Inc. reported plans to sell its Acute Care, Interventional Urology and OEM businesses to two buyers for $2.03 billion. Intersurgical Ltd. will acquire the Acute Care and Interventional Urology units for $530 million. Additionally, private equity firms Montagu and Kohlberg are buying its OEM contract manufacturing business for $1.5 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726732</guid>
      <pubDate>Tue, 09 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726732-teleflex-selling-3-business-units-for-203b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Businessman-signing-documents.webp?t=1738961282" type="image/jpeg" medium="image" fileSize="120407">
        <media:title type="plain">Businessman signing documents</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic’s Hugo robotic system gets FDA nod</title>
      <description>
        <![CDATA[The U.S. FDA’s clearance of Medtronic plc’s Hugo robotic-assisted surgery (RAS) system is certainly a boon for the company which is betting on the unit to be a key growth driver. While the soft tissue robotics market is dominated by Intuitive Surgical Inc.’s da Vinci system, the space is growing, and Medtronic has the scale, resources and market presence to make headway but there are also a plethora of smaller, versatile and cost-effective systems looking for a piece of the pie.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726721</guid>
      <pubDate>Mon, 08 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726721-medtronics-hugo-robotic-system-gets-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Medtronic-Hugo-platform-22aug25.webp?t=1771530746" type="image/jpeg" medium="image" fileSize="419119">
        <media:title type="plain">Medtronic Hugo platform</media:title>
        <media:description type="plain">Medtronic Hugo robotic-assisted surgery (RAS) system. Credit: Medtronic</media:description>
      </media:content>
    </item>
    <item>
      <title>Boston Sci brings next-generation Rezūm EVO Console to the UK</title>
      <description>
        <![CDATA[The first procedure to treat benign prostatic hyperplasia with Boston Scientific Corp.’s next-generation Rezūm EVO Console was successfully completed in the U.K. The device, which recently received CE mark, is intended to be used with the Rezūm Water Vapor Therapy, a minimally invasive treatment that uses water vapor to reduce prostate tissue. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/726477</guid>
      <pubDate>Fri, 05 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726477-boston-sci-brings-next-generation-rezm-evo-console-to-the-uk</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Rezum-5dec25.webp?t=1764972998" type="image/jpeg" medium="image" fileSize="263561">
        <media:title type="plain">Boston Scientific Rezum</media:title>
        <media:description type="plain">Boston Scientific Rezūm EVO Console. Credit: Boston Scientific</media:description>
      </media:content>
    </item>
    <item>
      <title>CMS terminates Treatment Choices model in ESRD final rule</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services ended the Treatment Choices model under the end stage renal disease payment payment system for several reasons, including its failure to deliver meaningful savings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726393</guid>
      <pubDate>Tue, 25 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726393-cms-terminates-treatment-choices-model-in-esrd-final-rule</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-logo-and-website.webp?t=1689968782" type="image/jpeg" medium="image" fileSize="122536">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Cornerstone Robotics raises $200M series D round</title>
      <description>
        <![CDATA[Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725991</guid>
      <pubDate>Fri, 14 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725991-chinas-cornerstone-robotics-raises-200m-series-d-round</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Cornerstone-Robotics-Sentire-Surgical-System-12nov25.webp?t=1763154095" type="image/jpeg" medium="image" fileSize="147992">
        <media:title type="plain">Cornerstone Robotics Sentire Surgical System</media:title>
        <media:description type="plain">Cornerstone Robotics Sentire Surgical System. Credit: Cornerstone Robotics Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Minze, Medtronic partner on overactive bladder care in EMEA</title>
      <description>
        <![CDATA[Minze Health NV signed a three-year agreement with Medtronic plc to bring its Minze Diary Pod, an app-controlled automated urine collection device, to markets across the EMEA region. The partnership aims to enhance the support services available for patients with overactive bladder receiving sacral neuromodulation therapy with Medtronic’s Interstim system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725972</guid>
      <pubDate>Wed, 12 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725972-minze-medtronic-partner-on-overactive-bladder-care-in-emea</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Bladder-cancer-illustration.webp?t=1744210757" type="image/jpeg" medium="image" fileSize="76477">
        <media:title type="plain">Illustration showing cross-section of bladder with tumor on bladder wall</media:title>
      </media:content>
    </item>
    <item>
      <title>Block enzymes tied to the androgen receptor, kill prostate tumors</title>
      <description>
        <![CDATA[Two enzymes from the protein disulphide isomerase (PDI) family enable prostate cancer cells to grow, survive, and resist treatment. This discovery, however, could be taken as an advantage to improve therapy for this type of tumor. Blocking the function of PDIA1 and PDIA5 leads to cancer cell death and a reduction in tumor size.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725259</guid>
      <pubDate>Fri, 17 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725259-block-enzymes-tied-to-the-androgen-receptor-kill-prostate-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Prostate-cancer-cells.webp?t=1765920543" type="image/png" medium="image" fileSize="389611">
        <media:title type="plain">Prostate cancer cells</media:title>
        <media:description type="plain">Prostate cancer cells</media:description>
      </media:content>
    </item>
    <item>
      <title>Roche secures CE mark for kidney disease algorithm</title>
      <description>
        <![CDATA[Roche Holdings AG received CE-mark for the Kidney Klinrisk algorithm, an AI-based tool developed in collaboration with Klinrisk Inc. to stratify risk and assess the progressive decline in kidney function. The software will help clinicians to make more informed decisions when accessing adults with chronic kidney disease as well as individuals with diabetes or hypertension who are at elevated risk of kidney function decline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724812</guid>
      <pubDate>Wed, 08 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724812-roche-secures-ce-mark-for-kidney-disease-algorithm</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Kidney-cancer-illustration.webp?t=1756411372" type="image/jpeg" medium="image" fileSize="565755">
        <media:title type="plain">Illustration of kidney cancer showing tumor inside the kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>Medtronic's Altaviva bags FDA approval for incontinence</title>
      <description>
        <![CDATA[Medtronic plc received U.S. FDA approval for Altaviva, a minimally invasive implantable tibial neuromodulation device designed to treat urge urinary incontinence. Insertion near the ankle requires neither sedation nor imaging and patients walk out the clinic door with the device already activated.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724134</guid>
      <pubDate>Fri, 19 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724134-medtronics-altaviva-bags-fda-approval-for-incontinence</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Medtronic-Altaviva-19sept25.webp?t=1758316875" type="image/jpeg" medium="image" fileSize="175059">
        <media:title type="plain">Medtronic Altaviva</media:title>
        <media:description type="plain">Medtronic plc's Altaviva. Credit: courtesy Medtronic</media:description>
      </media:content>
    </item>
    <item>
      <title>Organox liver perfusion device cleared by FDA during air transport</title>
      <description>
        <![CDATA[Organox Ltd.’s normothermic machine perfusion device, Metra, has been cleared by the U.S. FDA for use during air transport. The greenlight from the regulatory body paves the way for the broader use of donor organs that might otherwise be discarded, as the Metra system circulates oxygen and nutrient rich perfusate through the organ at near-body temperature, extending preservation times.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724133</guid>
      <pubDate>Fri, 19 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724133-organox-liver-perfusion-device-cleared-by-fda-during-air-transport</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/Organox-metra-7-18.webp?t=1689714374" type="image/jpeg" medium="image" fileSize="212077">
        <media:title type="plain">Organox metra</media:title>
        <media:description type="plain">Organox's metra device preserves donor livers and enables assessment of the organs prior to transplantation.</media:description>
      </media:content>
    </item>
    <item>
      <title>Pyroptosis-based therapeutic targets in neurogenic bladder</title>
      <description>
        <![CDATA[Neurogenic bladder is a disease involving inflammation and fibrosis of the bladder. Fibrosis has been linked to the type of programmed cell death known as pyroptosis, which in turn has been linked to cGAS-STING signaling and subsequent activation of the NLRP3 inflammasome. Researchers at Children’s Hospital of Chongqing Medical University wondered whether the same processes contribute to the fibrosis in neurogenic bladder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723592</guid>
      <pubDate>Tue, 26 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723592-pyroptosis-based-therapeutic-targets-in-neurogenic-bladder</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Art-concept-for-bladder.webp?t=1733435225" type="image/jpeg" medium="image" fileSize="250443">
        <media:title type="plain">Art concept for bladder</media:title>
      </media:content>
    </item>
    <item>
      <title>Teleflex closes $879M Biotrinik buy, wraps strong Q2</title>
      <description>
        <![CDATA[Good news bracketed July for Teleflex Inc. as it completed the acquisition of the vascular intervention business of Berlin-based Biotronik SE & Co. for €760 million (US$879 million) on July 1 and released stronger-than-expected second quarter results on the closing day of the month. Both bode well for the company as it proceeds through a thorough restructuring announced in February.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722644</guid>
      <pubDate>Mon, 04 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722644-teleflex-closes-879m-biotrionik-buy-wraps-strong-q2</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.webp?t=1729025266" type="image/jpeg" medium="image" fileSize="220776">
        <media:title type="plain">Gold Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Uromems gets OK for Uroactive stress urinary incontinence trial</title>
      <description>
        <![CDATA[Uromems SAS received investigational device exemption (IDE) approval from the U.S. FDA, and clearance from the French National Agency for the Safety of Medicines and Health Products (ANSM), to begin a pivotal trial of its Uroactive smart implant. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721973</guid>
      <pubDate>Thu, 17 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721973-uromems-gets-ok-for-uroactive-stress-urinary-incontinence-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Uroactive-smart-implant-7-17.webp?t=1752787341" type="image/png" medium="image" fileSize="279937">
        <media:title type="plain">Uroactive smart implant</media:title>
        <media:description type="plain">Uroactive smart implant. Credit: Uromems SAS</media:description>
      </media:content>
    </item>
    <item>
      <title>Comphya secures $8.4M for implantable neurostimulation ED therapy</title>
      <description>
        <![CDATA[Comphya SA raised CHF 7.5 million (US$ 8.4 million) in a series A round for its implantable neurostimulation therapy, Caverstim, which treats men with erectile dysfunction who do not respond to medication.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721942</guid>
      <pubDate>Mon, 14 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721942-comphya-secures-84m-for-implantable-neurostimulation-ed-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Caverstim-system-14july25.webp?t=1752530976" type="image/jpeg" medium="image" fileSize="123089">
        <media:title type="plain">Caverstim system</media:title>
        <media:description type="plain">Caverstim system. Credit: Comphya</media:description>
      </media:content>
    </item>
    <item>
      <title>CMS formally proposes to terminate ESRD choices program</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services indicated it will act on a previous proposal to terminate the Treatment Choices Model for ESRD at the end of the current calendar year because of a failure of the program to deliver on the promised efficiencies and improvement in outcomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721795</guid>
      <pubDate>Tue, 08 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721795-cms-formally-proposes-to-terminate-esrd-choices-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Accunea’s Renosure device can save kidneys from being discarded</title>
      <description>
        <![CDATA[Accunea Ltd.’s bioanalysis technology, Renosure, can measure creatinine clearance in machine perfused kidneys, according to data presented at the recent European Society of Organ Transplantation 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721786</guid>
      <pubDate>Mon, 07 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721786-accuneas-renosure-device-can-save-kidneys-from-being-discarded</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Accunea-monitoring-device-7july25.webp?t=1751922234" type="image/jpeg" medium="image" fileSize="196881">
        <media:title type="plain">Accunea monitoring device</media:title>
        <media:description type="plain">Accunea’s Renosure monitoring device. Credit: Accunea</media:description>
      </media:content>
    </item>
    <item>
      <title>Vantive to invest $1B in digital kidney support therapies</title>
      <description>
        <![CDATA[Vantive Health LLC, formerly the kidney care business of Baxter International Inc., plans to invest $1 billion over the next five years in development of digitally enabled dialysis products, innovation in acute organ support therapy options and expanding production capacity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720639</guid>
      <pubDate>Tue, 03 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720639-vantive-to-invest-1b-in-digital-kidney-support-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-dna-gene-therapy.webp?t=1747406414" type="image/jpeg" medium="image" fileSize="710010">
        <media:title type="plain">Illustration of kidneys with DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>Phraxis Endoforce receives FDA approval for anastomosis</title>
      <description>
        <![CDATA[The U.S. FDA approved Phraxis Inc.’s Endoforce Connector for endovascular venous anastomosis, which eliminates the need for surgical dissection for individuals undergoing hemodialysis for kidney failure. The device is designed to reduce tissue trauma and improve long-term graft performance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720279</guid>
      <pubDate>Fri, 23 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720279-phraxis-endoforce-receives-fda-approval-for-anastomosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/phraxis-endoforce-23may25.webp?t=1748035267" type="image/jpeg" medium="image" fileSize="81373">
        <media:title type="plain">Phraxis Endoforce</media:title>
        <media:description type="plain">Phraxis Endoforce. Credit: courtesy Phraxis</media:description>
      </media:content>
    </item>
    <item>
      <title>Hinge Health rings NYSE bell as IPO raises $437M</title>
      <description>
        <![CDATA[Hinge Health Inc.’s flexibility produced big rewards as the digital therapy company for physical rehabilitation finally began trading on the NYSE under the symbol HNGE on May 22 after delaying its IPO twice. Hinge co-founders Daniel Perez and Gabriel Mecklenburg rang the opening bell for the stock exchange to celebrate the offering’s $437 million haul.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720269</guid>
      <pubDate>Thu, 22 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720269-hinge-health-rings-nyse-bell-as-ipo-raises-437m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Urine-testing device turns toilets into health trackers</title>
      <description>
        <![CDATA[In what represents just the company’s third PCT filing, Houston-based Starling Medical Inc.’s co-founders, Hannah McKenney and William Hendricks, seek to gain further protection for their at-home urine diagnostic patient-monitoring platform that eliminates the traditional use of catching containers and dipsticks.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719944</guid>
      <pubDate>Fri, 16 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719944-urine-testing-device-turns-toilets-into-health-trackers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/urine-testing-device-16may25.webp?t=1747425021" type="image/jpeg" medium="image" fileSize="115210">
        <media:title type="plain">urine testing device</media:title>
        <media:description type="plain">WO2025090837-A1, “Bodily fluid management system.”Assignee: Starling Medical Inc.Inventors: McKenney, Hannah; Hendricks, William AndrewIPC codes: G01N 33/493; G01N 15/075; G01N 15/14; A61B 5/20; A61B 5/00; A61B 10/00Publication date: May 1, 2025Earliest priority details: US2023593148, Oct. 25, 2023</media:description>
      </media:content>
    </item>
    <item>
      <title>Kidneyintelx test leads to increased use of SGLT2 inhibitors</title>
      <description>
        <![CDATA[The use of Renalytix plc’s Kidneyintelx biomarker-based prognostic test led to increased and targeted use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients at risk of diabetic kidney disease, compared to untested patients, according to data from a study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719406</guid>
      <pubDate>Wed, 23 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719406-kidneyintelx-test-leads-to-increased-use-of-sglt2-inhibitors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Kidney-disease.webp?t=1722874886" type="image/jpeg" medium="image" fileSize="280482">
        <media:title type="plain">Illustration of diseased kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>Predict4Health rebrands as Okeiro, raises €10M for transplantation predictive tool</title>
      <description>
        <![CDATA[French startup Predict4Health SAS rebranded to Okeiro and raised €10 million (US$11.35 million).]]>
      </description>
      <guid>http://www.bioworld.com/articles/719151</guid>
      <pubDate>Thu, 17 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719151-predict4health-rebrands-as-okeiro-raises-10m-for-transplantation-predictive-tool</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Okeiro-Ibox-17apr25.webp?t=1744919743" type="image/jpeg" medium="image" fileSize="294742">
        <media:title type="plain">Okeiro box</media:title>
        <media:description type="plain">Okeiro Ibox technology. Credit: Okeiro</media:description>
      </media:content>
    </item>
    <item>
      <title>Uresta raises $3M to stop urinary leaks</title>
      <description>
        <![CDATA[Resilia Inc., dba Uresta, raised $3 million to launch its device to stop stress urinary incontinence in women. The flexible, insertable device braces the bladder and compresses the urethral passage to reduce or eliminate leakage during exercise, when coughing or laughing or when a woman just doesn’t want to worry about it. BDC Capital led the funding with a $1.5 million investment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718264</guid>
      <pubDate>Wed, 26 Mar 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718264-uresta-raises-3m-to-stop-urinary-leaks</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/gastrointestines-female-bowel-fecal-incontinence.webp?t=1635802900" type="image/png" medium="image" fileSize="516578">
        <media:title type="plain">Partial view of woman holding paper made intestines over stomach</media:title>
      </media:content>
    </item>
    <item>
      <title>Investors brings Relief funds for stress urinary incontinence device</title>
      <description>
        <![CDATA[Relief Srl raised more than €1 million (US$1.08 million) in financing for Urorelief, its endourethral medical device which treats stress urinary incontinence. The Italian startup will use the funds to conduct clinical trials to validate the device as it looks to transform the lives of men and women suffering from the condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717734</guid>
      <pubDate>Thu, 06 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717734-investors-brings-relief-funds-for-stress-urinary-incontinence-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Euro-currency-symbol-white.webp?t=1669153720" type="image/png" medium="image" fileSize="307769">
        <media:title type="plain">White Euro symbol on blue background</media:title>
      </media:content>
    </item>
  </channel>
</rss>
